ANIP · Ani Pharmaceuticals Inc · Executive Compensation
$72.40
-0.57 (-0.77%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.67B
Shares
22.97M
Volume · Oct 2
35.16K
Avg daily vol (3M)
372.7K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $10,278,620 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $3,396,694 |
| Stephen Carey | Senior Vice President, Finance and Chief Financial Officer | $3,251,862 |
| Meredith W. Cook | Senior Vice President, General Counsel and Corporate Secretary | $2,318,421 |
| Ori Gutwerg | Senior Vice President, Generics | $2,309,559 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $8,859,402 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,850,468 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $2,417,672 |
| Ori Gutwerg | Senior Vice President, Generics | $2,107,942 |
| Meredith W. Cook | Senior Vice President, General Counsel and Corporate Secretary | $2,022,480 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $8,078,353 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,576,088 |
| Ori Gutwerg | Senior Vice President, Generics | $1,941,690 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $1,914,451 |
| Chad Gassert | Senior Vice President, Corporate Development and Strategy | $1,896,243 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $5,112,087 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,039,584 |
| James G. Marken | Senior Vice President, Operations and Product Development | $1,431,494 |
| Ori Gutwerg | Senior Vice President, Generics | $1,362,928 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $1,304,213 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $6,541,060 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,850,554 |
| James G. Marken | Senior Vice President, Operations and Product Development | $1,734,653 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $1,605,932 |
| Ori Gutwerg | Senior Vice President, Generics | $1,519,337 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $3,715,036 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,754,577 |
| Robert W. Schrepfer | Former Senior Vice President, New Business Development and Specialty Sales | $2,658,963 |
| James G. Marken | Senior Vice President, Operations and Product Development | $1,874,535 |
| Patrick Walsh | CEO | $962,213 |
| Patrick D. Walsh | Former Interim President and Chief Executive Officer | $962,213 |
| Arthur Przybyl | Former President and Chief Executive Officer | $857,814 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Arthur Przybyl | Former President and Chief Executive Officer | $5,815,760 |
| Robert W. Schrepfer | Former Senior Vice President, New Business Development and Specialty Sales | $2,160,975 |
| Stephen Carey | Senior Vice President, Finance and Chief Financial Officer | $2,156,392 |
| James G. Marken | Senior Vice President, Operations and Product Development | $1,398,766 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Arthur Przybyl | Former President and Chief Executive Officer | $4,197,933 |
| Robert W. Schrepfer | Former Senior Vice President, New Business Development and Specialty Sales | $1,444,156 |
| Stephen Carey | Senior Vice President, Finance and Chief Financial Officer | $1,438,750 |
| James G. Marken | Senior Vice President, Operations and Product Development | $1,009,589 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Arthur Przybyl | President, Chief Executive Officer and Director | $3,580,292 |
| Stephen Carey | Vice President, Finance and Chief Financial Officer | $1,246,557 |
| Robert W. Schrepfer | Senior Vice President, New Business Development and Specialty Sales | $1,245,325 |
| James G. Marken | Senior Vice President, Operations and Product Development | $875,495 |